Evolution of the Average Target: Virbac

Data source: Virbac(VIRP)
Evolution of the Average Target - Virbac

Evolution of the Target Price: Virbac

Data source: Virbac(VIRP)
Evolution of the Target Price - Virbac

Changes in Analyst Recommendations: Virbac

Data source: Virbac(VIRP)
ed857447.x5SsUoZBRXMyJxOqfgHYQmu8mGghp2YxkAp5363_e8E.rKD_Y-svHQZDVSPwL168Ixno0h1T7BdJ2U5LlJScNPaDx4EethkdS1R2Rg~9401275d9b88d36a1a972b7bd370378c
20/08 Cancer vaccines finally garner the spotlight Alphavalue
22/07 Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 Alphavalue
15/07 Where would AI lead Pharma in the long run? Alphavalue
11/05 Virbac continues decline despite positive recommendation Zonebourse
18/04 Virbac: 2026 starts on strong footing Alphavalue
19/03 Stifel sees Virbac as undervalued, sets 440 euro price target Zonebourse
18/03 Virbac in the green following results and outlook Zonebourse
21/01 Virbac beats 2025 targets, lifts 2026 outlook Alphavalue
20/01 Stifel Raises Price Target on Virbac Zonebourse
20/01 Virbac Significantly Outperforms the Market with Annual Revenues and 2026 Targets Zonebourse
18/10/25 Virbac: Q3 crushed doubts about execution ability Alphavalue
17/09/25 The day the Fed resumed its rate cuts Zonebourse
15/09/25 Virbac: Oddo BHF remains positive despite H1 results Zonebourse
18/07/25 Virbac: A healthy Q2 impresses the markets Alphavalue
04/07/25 Oddo BHF Upgrades Virbac to Outperform, Boosts PT MT
03/07/25 Virbac: Oddo BHF upgrades stock Zonebourse
17/04/25 Virbac: brokers' advice following quarterly results Zonebourse
16/04/25 Virbac: Stifel remains bullish after quarterly results Zonebourse
16/04/25 Virbac: Decent Q1; Clarity on US tariff exposure was a key takeaway Alphavalue
16/04/25 Virbac: Stifel still buying after Q1 results Zonebourse
18/03/25 Virbac: Oddo BHF remains 'neutral', confirms its target Zonebourse
17/03/25 Virbac: 2024 profitability somewhat exceeded expectations; stock re-rating underway Alphavalue
17/03/25 Virbac: Stifel raises its recommendation Zonebourse
18/01/25 Virbac: 2024 top-line goals met; uninspiring 2025 outlook could be raised later Alphavalue
17/01/25 Oddo BHF Downgrades Virbac to Neutral, Cuts PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+14.8%
+9.76%
+5.1%
+10.16%
+7.39%
+7.01%
+32.09%
-2.92%
+10%
Average +10.38%
Weighted average by Cap. +10.94%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
312.00EUR
Average target price
412.75EUR
Spread / Average Target
+32.29%
High Price Target
440.00EUR
Spread / Highest target
+41.03%
Low Price Target
360.00EUR
Spread / Lowest Target
+15.38%

Analyst Consensus Detail

Analyst consensus - Virbac

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Virbac
Trader
Investor
Global
Quality
ESG MSCI
AA
Ratings Surperformance© - Virbac